DreamCIS Inc (223250) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of DreamCIS Inc stock KRW 8,287, price KRW 4,050, upside +104.6%, quality 58 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 2,378 KRW – 7,840 KRW · fair‑value band 5,801 KRW – 10,774 KRW · the 4,050 KRW price screens below the 8,287 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow DreamCIS in your weekly email
Every Wednesday you see whether DreamCIS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DreamCIS, Inc. operates as a clinical research organization in South Korea.
Show moreShow less
It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services.
The company was founded in 2000 and is headquartered in Seoul, South Korea. DreamCIS, Inc. operates as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd.
Stock analysis
DreamCIS Inc (223250) currently trades at 4,050 KRW, while our model-based Fair Value estimate is 8,287 KRW, implying the stock looks roughly 51% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 10,478 KRW per share, and 19 of the 24 models we run sit above the 4,050 KRW price.
Bear case: the Asset-Based group reads lowest at 1,229 KRW, and 5 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 5,801 KRW (bear) to 10,774 KRW (bull), the price of 4,050 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
DreamCIS Inc reported revenue of 66.6B KRW in FY2025 versus 26.2B KRW in FY2021, a compound +26.3%/yr. Reported net income was 7.1B KRW in FY2025, compounding +21.9%/yr from FY2021.
Key figures
Market cap 96.4B KRW (≈ $71.3M) Micro · P/E ratio 307.3 · P/S ratio 1.32 · EPS (TTM) 13.37 KRW · Net margin 0.5% · Return on equity 0.8% · Return on assets (EBIT) 4.6% (5-year average) · Operating margin 11.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 65% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 105%, 223250 screens cheaper than that median.
Fair Value models
Bear5,801 KRWFair Value 8,287 KRWBull10,774 KRW
Price 4,050 KRW · Upside +104.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (11.46 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+13.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.6%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ −23.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−23.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 8%
⚠ Revenue per share shrinking 10.4%/yr over ~6Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Rate on operating basis: 2025 sits 57% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−8.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −10.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside+104.6% · Top 25%
Profitability
Return on equity (12 months)0.8% · Bottom 25%
Return on assets4.4% · Above median
Net margin (12 months)0.5% · Bottom 25%
Operating margin (12 months)11.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)20.5% · Top 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DreamCIS Inc Fair Value". https://www.fairvalue-calculator.com/stock/223250
Frequently asked questions
Is DreamCIS Inc (223250) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 8,287 KRW versus a price of 4,050 KRW, about +105% upside (undervalued).
What is the fair value of 223250?
Our model-based fair value for DreamCIS Inc is 8,287 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 4,050 KRW.
What is the quality score of 223250?
DreamCIS Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DreamCIS Inc (223250)?
Our model-based price target is the fair value of 8,287 KRW (as of Nov 9, 2026) from 24 valuation models. Cautious scenario 5,801 KRW, optimistic scenario 10,774 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DreamCIS Inc stock forecast for 2026?
Our models put fair value at 8,287 KRW, about +105% upside versus a price of 4,050 KRW (undervalued). Cautious scenario 5,801 KRW, optimistic scenario 10,774 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DreamCIS Inc (223250)?
DreamCIS Inc reported trailing-twelve-month revenue of about 73.3B KRW (latest available figure, as of Nov 9, 2026).
What growth is priced into DreamCIS Inc (223250)?
For today's price to be fair in a discounted-cash-flow model, DreamCIS Inc would have to grow free cash flow by -8.7 % per year for five years (discount rate 11.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +23.2 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 223250 use?
Our models discount DreamCIS Inc at 11.7 %: a base by market capitalisation (micro), damped by beta 0.56, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DreamCIS Inc that is -8.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.7 %) and the same formula as our fair value.
How much growth has DreamCIS Inc (223250) delivered so far?
Over the past 5 years revenue at DreamCIS Inc grew +23.2 % a year. The price currently implies free-cash-flow growth of -8.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DreamCIS Inc (223250) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into DreamCIS Inc (-8.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DreamCIS Inc (223250)?
The free-cash-flow yield on the price is 13.90 %: that much free cash flow DreamCIS Inc produces per unit of market value. When it exceeds the discount rate of our models (11.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DreamCIS Inc (223250)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DreamCIS Inc it is 8,287 KRW per share (as of Nov 9, 2026), against a price of 4,050 KRW. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is DreamCIS Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 223250 trades below its calculated fair value: price 4,050 KRW, fair value 8,287 KRW, a gap of about +105% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 223250?
No. The price is what the market pays today (4,050 KRW); the fair value is what the company's own numbers justify (8,287 KRW). For DreamCIS Inc the two are 4,237 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DreamCIS Inc worth?
The market values DreamCIS Inc at about 96.4B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 4,050 KRW; our models calculate a fair value of 8,287 KRW per share.
What do the bullish and bearish scenarios say about 223250?
Our models span a range for DreamCIS Inc: cautious scenario 5,801 KRW, base 8,287 KRW, optimistic 10,774 KRW per share (as of Nov 9, 2026, price 4,050 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 223250?
DreamCIS Inc trades at a price-to-earnings ratio of 307.3 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 8,287 KRW is built from several models across several years. Other multiples: P/B 1.3, P/S 1.3, EV/EBITDA 9.0.
How solid is the balance sheet of DreamCIS Inc (223250)?
Balance-sheet figures for DreamCIS Inc (as of Nov 9, 2026): return on equity 0.8%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 223250 from its 52-week high?
DreamCIS Inc trades at 4,050 KRW, about 47% below its 52-week high of 7,690 KRW and 65% above the low of 2,450 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 8,287 KRW is for.
Which stocks are comparable to DreamCIS Inc?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DreamCIS Inc stock attractive at the current price?
The data as of Nov 9, 2026: price 4,050 KRW, calculated fair value 8,287 KRW (+105%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 223250 calculated?
We run DreamCIS Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 8,287 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. DreamCIS Inc currently trades 51% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DreamCIS Inc (223250)?
The closing price on Nov 6, 2026 was 4,050 KRW. Our model-based fair value is 8,287 KRW, about +105% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DreamCIS Inc right now?
The price is below even our cautious bear case (5,801 KRW). The market is more pessimistic than our downside scenario. Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (5,801 KRW to 10,774 KRW) leaves room in how you read the outcome.
Key figures of DreamCIS Inc
How large is the market capitalisation of DreamCIS Inc (223250)?
The market capitalisation of DreamCIS Inc is 96.4B KRW (≈ $71.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DreamCIS Inc (223250)?
The price-to-sales ratio of DreamCIS Inc is 1.32 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DreamCIS Inc (223250)?
Earnings per share at DreamCIS Inc are 13.37 KRW (price ÷ EPS = P/E 307.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of DreamCIS Inc (223250)?
The net margin of DreamCIS Inc is 0.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DreamCIS Inc (223250)?
The return on equity (ROE) of DreamCIS Inc is 0.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DreamCIS Inc (223250)?
On an EBIT basis the return on assets of DreamCIS Inc is 4.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DreamCIS Inc (223250)?
The operating margin of DreamCIS Inc is 11.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DreamCIS Inc (223250)?
Revenue at DreamCIS Inc is growing +20.5% versus a year earlier (3y avg +19.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DreamCIS Inc (223250)?
Earnings per share at DreamCIS Inc are growing +981% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch DreamCIS Inc in the live analysis
One click puts DreamCIS Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026